Business Wire Feed
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure
BEIJING--(BUSINESS WIRE)--Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput more...
Agilent Launches Multi-Attribute Method (MAM) Solution for BioPharma Quality Control
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of a new multi-attribute method (MAM) workflow designed to help pharmaceutical and biopharmaceutical quality control (QC) laboratories implement liquid chromatography high-resolution mass spectrometry more...
Aphios Corporation Announces Notice of Allowance for Novel Bryoid Composition Patent Targeting Alzheimer’s Disease, Multiple Sclerosis, HIV Latency and Cancer
NORTH READING, Mass.--(BUSINESS WIRE)--#Alzheimers--Aphios Corporation today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a divisional patent application titled “Bryoid Compositions, Methods of Making and Use more...
Biomunex Announces Strategic Artificial Intelligence Collaborations to Further Accelerate the Discovery and Development Processes of Its Innovative Pipeline of Cancer Immunotherapies
Collaborations with Gordion Bioscience and Tangramed Biotech, two AI-specialized companies, further strengthen Biomunex's integration of artificial intelligence (AI) into its R&D activities and support the development of next generation immunotherapies in oncologyPARIS & CAMBRIDGE, Mass.--(BUSINESS more...
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of careALISO VIEJO, Calif.--(BUSINESS WIRE)--#FLIGHTglaucoma--ViaLase, Inc., more...
Swoop Acquires Nimble, Adding Prescription Fulfillment and Pharmacy Connectivity to Portfolio
NEW YORK--(BUSINESS WIRE)--Swoop, a leader in AI-driven, data-powered, and privacy-compliant healthcare engagement, today announced the acquisition of Nimble, a leading prescription management platform. Across independent pharmacies in all 50 states, Nimble enables 16 million patients more...
Unio Health Partners and Thesis Care Announce Partnership to Scale AI-Powered Clinical Teams Across Specialty Care
Multi-specialty physician platform deploys multiple Thesis AI care team agents across practices serving more than 500,000 patientsNEW YORK & TORRANCE, Calif.--(BUSINESS WIRE)--Thesis Care, the AI-powered care team platform for scalable clinical capacity, and Unio Health more...
Inocras Announces ASCO 2026 Online Publication: Whole-genome HRD phenotyping as a predictor of PARP inhibitor benefit in first-line maintenance high-grade serous ovarian cancer
Study conducted with Severance Hospital shows whole-genome sequencing-based HRD phenotyping was associated with longer progression-free survival in patients receiving PARP inhibitor maintenance therapySAN DIEGO & SEOUL, South Korea--(BUSINESS WIRE)--#CancerGenome--Inocras, a bioinformatics-led company harnessing the power more...
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
– Chronic HDV is considered the most severe form of viral hepatitis due to rapid disease progression towards liver failure and liver-related death – – Approval introduces the first FDA-approved therapy for this disease with more...
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist more...
Zelis Recognized as a 2026 Great Place to Work® in the U.S. and India
Certification in consecutive years reflects Zelis’ continued investment in culture, professional growth, and associate wellbeingBOSTON--(BUSINESS WIRE)--Zelis, a leading provider of healthcare technology solutions, is certified as a Great Place to Work® in both the United more...
HealthNet and AndHealth Celebrate Pharmacy Ribbon Cutting at Barrington Location, Improving Medication Access Across Central Indiana
INDIANAPOLIS, Ind.--(BUSINESS WIRE)--HealthNet and AndHealth celebrated the ribbon cutting of the newly opened HealthNet Pharmacy this week, marking a major investment in affordable pharmacy access, integrated specialty care, and medication support services for patients across more...
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia more...
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with an unprecedented median overall survival of approximately two years based on the TROPION-Breast02 more...
PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026
Two-year and post-hoc SURPASS-ET analyses highlight the impact of treatment timing, with durable responses and improved progression-free survival supporting consideration of earlier ropeginterferon alfa-2b use in high-risk ET following hydroxyurea intolerance or resistance First presentation more...
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Daiichi Sankyo and AstraZeneca’s Datroway is the only TROP2 directed antibody drug conjugate to prolong overall survival in this setting versus chemotherapy, with an unprecedented median overall survival of approximately two years based on the more...
Hyperfine Announces Presentation of Results from the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency Departments
Prospective randomized ED study shows rapid bedside imaging, detection of critical neurological findings, and potential workflow efficiency benefits with portable MRIGUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain more...
ClearNote Health to Present Early Detection Validation Data for Avantect® Pancreatic Cancer Test at 2026 ASCO Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--#5hmC--ClearNote Health, a company dedicated to improving early detection for some of the deadliest cancers, today announced it will present new multi-cohort validation data for its Avantect® Pancreatic Cancer Test at the 2026 more...
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
TOKYO--(BUSINESS WIRE)--Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who more...
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
Opinion granted based on positive event-free survival, overall survival and pathologic complete response rate results from the Phase 3 KEYNOTE-905 trial If approved, this combination would become the first and only PD-1 inhibitor plus antibody-drug more...
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
– Recommendation Based on ASCENT-03 Study, Demonstrating Highly Statistically Significant and Clinically Meaningful Progression-Free Survival Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients– – Positive Opinion Marks a Significant Step Towards Introducing a Crucial First-line Treatment more...
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce more...
Boys & Girls Clubs of America Expands Trauma-Informed Approach to Advance Youth Mental Wellness Nationwide
The organization and its partners are expanding access to trusted adults, safe spaces, and trauma-informed support to help millions of kids and teens build resilience and thriveATLANTA--(BUSINESS WIRE)--As conversations around mental health take center stage more...
ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
Analysis demonstrates a lower cost per sustained responder and cystectomy avoided with ANKTIVA plus BCG compared to TAR-200 in Medicare population over three yearsCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today more...
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
UK-based study identifies key patient-centered factors influencing treatment preferences in high-risk NMIBCCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced new survey data highlighting the diverse treatment preferences and decision-making priorities more...